3 курс / Фармакология / Диссертация_Ромодановский_Д_П_Разработка_требований_для_оценки_фармакокинетики

302.Mansour, N.O. Validated RP-HPLC method for quantification of doxazosin in human plasma: Application in a bioequivalence study / N.O. Mansour // Ann Pharm Fr. - 2020. - 78(1).

-P. 42-48.

303.Manzoli, L. Generic versus brand-name drugs used in cardiovascular diseases / L. Manzoli, M.E. Flacco, S. Boccia [et al.] // Eur. J. Epidemiol. – 2016. – 31. – P. 351–368.

304.Markoula, S. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting / S. Markoula, D. Chatzistefanidis, S. Gatzonis [et al.] // Seizure. - 2017. -48(05).

-P. 1-6.

305.Marzo, A. Open questions on bioequivalence: some problems and some solutions / A. Marzo // Pharmacological Research. - 1999. - 40(4). - P. 357–368.

306.Marzo, A. Open questions on bioequivalence: the case of cholecalciferol / A. Marzo, A. Barassi, E. Porro // Italian Journal of Medicine. - 2013. - P. 156–159.

307.Matji, A. Effect of enantiomerism on the bioequivalence of a new ibuprofen 600-mg tablet formulation obtained by roller compaction / A. Matji, E. Vargas, L. Carvajal [et al.] // Chirality. - 2020. - 32(2). - P. 185-190.

308.Mattison, D.R. Pharmacokinetics in real life: sex and gender differences / D.R. Mattison // J. Popul. Ther. Clin. Pharmacol. - 2013. - 20(3). - P. 340-349.

309.Maurer, W. Controlling the type error rate in two-stage sequential adaptive designs when testing for average bioequivalence / W. Maurer, B. Jones, Y. Chen // Stat Med. – 2018. – 37. –

P. 1587-607.

310.Mehta, M.U. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development / M.U. Mehta, RS. Uppoor, D.P. Conner [et al.] // Mol Pharm. - 2017. - 14(12). - P. 4334-4338.

311.Menke, A. Absolute bioavailability of folic acid after oral administration of a folic acid tablet formulation in healthy volunteer / A. Menke, H.J. Weimann, G. Achtert [et al.] // Arzneimittelforschung. - 1994. - 44(9). - P. 1063-1077.

312.Mentaverri, R. Pharmacokinetics of a New Pharmaceutical Form of Vitamin D3 100,000 IU in Soft Capsule / R. Mentaverri, JC. Souberbielle, G. Brami [et al.] // Nutrients. - 2019. - 11(3). - P. 703.

313.Micheal, F. Has the time come to employ population and individual bioequivalence for the evaluation of generics? / F. Micheal, M. Sayana, R. Prasad [et al.] // Curr Drug Metab. –

2020. – 21. P. 1.

314.Midtvedt, K. Generic drugs – not as equivalent as we think? / K. Midtvedt, I. Robertsen,

A. Åsberg // Tidsskr Nor Laegeforen. – 2019. - 139(18). - doi: 10.4045/tidsskr.19.0740.

371

315.Min, M.H. Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers / M.H. Min, J.H. Park, J.H. Hur [et al.] // Drug Des Devel Ther. - 2019. - 13(04). - P. 1049-1058.

316.Mitra, A. Application of absorption modeling to predict bioequivalence outcome of two batches of etoricoxib tablets / A. Mitra, F. Kesisoglou, P. Dogterom // AAPS PharmSciTech. –

2015. – 16. – P. 76–84.

317.Mitra, A. Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products / A. Mitra, B. Petek, A. Bajc [et al.] // Eur J Pharm Biopharm. - 2019. - 134(01). - P. 117-125.

318.Mohanty, L. Bioequivalence of two tacrolimus 1-mg formulations under fasting conditions in healthy subjects: A randomized, two-period crossover trial / L. Mohanty, S.

Bhushan, B. Rüttger // Int J Clin Pharmacol Ther. – 2020. - 58(3). - P. 183-193.

319.Moon, S.J. Comparative pharmacokinetic and tolerability evaluation of two simvastatin 20 mg formulations in healthy Korean male volunteers / S.J. Moon, S. Lee, K. Jang [et al.] // Transl Clin Pharmacol. - 2017. - 25(1). - P. 10-14.

320.Moreno, I. Effect of Truncating AUC at 12, 24 and 48 hr When Evaluating the Bioequivalence of Drugs with a Long Half-Life / I. Moreno, D. Ochoa, M. Román [et al.] // Basic

Clin Pharmacol Toxicol. - 2016. - 118(1). - P. 53-7.

321. Moreno, I. Utility of Pilot Studies for Predicting Ratios and Intrasubject Variability in High-Variability Drugs / I. Moreno, D. Ochoa, M. Román [et al.] // Basic Clin Pharmacol

Toxicol. - 2016. - 119(2). - P. 215-21.

322.Multisource (generic) pharmaceutical products: guidelines on registration requirements

to establish interchangeability (Annex 7). [Электронный ресурс] // World Health Organization.

https://www.who.int/medicines/areas/quality_safety/quality_assurance/Annex7-TRS992.pdf

(дата обращения: 11.05.2020).

323.Munoz, J., Consumer’s risk in the EMA and FDA regulatory approaches for

bioequivalence in highly variable drugs / J. Munoz, D. Alcaide, J. Ocana // Stat Med. – 2016. –

35. – P. 1933–1943.

324.Murru, A. A study on the bioequivalence of lithium and valproate salivary and blood levels in the treatment of bipolar disorder / A. Murru, M. Torra, A. Callari [et al.] // Eur Neuropsychopharmacol. - 2017. - 27(8). - P. 744-750.

325.Nawaz, H.A. Evaluation of gender difference in pharmacokinetics of Candesartan cilexetil in the fasted state by RP-HPLC: A single dose comparative study / H.A. Nawaz, M.I. Masood, M. Abbas [et al.] // Pak J Pharm Sci. – 2019. - 32(3). – P. 1019-1024.

372

326.Ni, Y. Bioequivalence assessment of ambroxol orally-disintegrating tablet after a single oral-dose administration to healthy volunteers / Y. Ni, L. Hou, L. Chen [et al.] // Int J Clin Pharmacol Ther. - 2016. - 54(5). - P. 399-404.

327.Nishida, C. The Bioequivalence and Effect of Food on the Pharmacokinetics of a FixedDose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects / C. Nishida, Y. Matsumoto, K. Fujimoto [et al.] // Clin Transl Sci. - 2019. - 12(6). - P. 704-712.

328.Niwa, T. Evaluation of the pharmacokinetic parameters of standard oral antibiotics in a bioequivalence study of generic products / T. Niwa, T. Hata, M. Hayashi [et al.] // Pharmazie. - 2016. - 71(7). - P. 363-377.

329.Nokelainen, H. Reasons for allowing and refusing generic substitution and factors determining the choice of an interchangeable prescription medicine: a survey among pharmacy

customers in Finland / H. Nokelainen, E. Lämsä, R. Ahonen [et al.] // BMC Health Serv Res. –

2020. - 20(1). – P. 82.

330.nQuery: Sample size and power calculation for successful clinical trials [Электронный ресурс]. URL https://www.statsols.com/nquery. (дата обращения: 11.05.2020).

331.Ocaña, J. Controlling type I error in the reference-scaled bioequivalence evaluation of highly variable drugs / J. Ocaña, J. Muñoz // Pharm Stat. – 2019. -18(5). P. 583-599.

332.Oh, M. Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers / M. Oh, SE. Park, JL. Ghim [et al.] // Drug Des Devel Ther. - 2017. - 11(12). - P. 3543-3550.

333.Oh, M. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects / M. Oh, JG. Shin, S. Ahn [et al.] // Drug Des Devel Ther. - 2019. - 13(04). - P. 991-997.

334.Oh, M.J. Bioequivalence Study of a New Fixed-dose Combination Tablet Containing S- Amlodipine Nicotinate and Olmesartan Medoxomil in Healthy Korean Male Subjects / MJ. Oh,

HH.Hwang, HG. Kim [et al.] // Clin Ther. - 2017. - 39(7). - P. 1371-1379.

335.Oishi, M. Different truncation methods of AUC between Japan and the EU for bioequivalence assessment: influence on the regulatory judgment / M. Oishi, K. Chiba, T. Fukushima // Drug Metabolism and Pharmacokinetics. - 2012. - 5(27). - P. 658-662.

336.Okour, M. A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects / M. Okour, A. Puri,

G.Chen [et al.] // Clin Ther. - 2019. - 41(6). - P. 1110-1127.

337.Ölçer, A. The advantages of combination therapy on hypertension: development of

immediate release perindopril-indapamide tablet and assessment of bioequivalence studies / A.

Ölçer, M. Ölçer, I. İnce [et al.] // Pharm Dev Technol. - 2016. - 21(2). - P. 239-49.

373

338.Opara, J. Prediction of pharmacokinetic parameters and the assessment of their variability in bioequivalence studies by artificial neural networks / J. Opara, S. Primozic, P. Cvelbar // Pharm Res. - 1999. - 16(6). - P. 944-8.

339.Otoul, C. Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50-mg Film-Coated Tablet / C. Otoul, S. Watanabe, S. McCabe [et al.] // Clin Pharmacol Drug Dev. - 2017. -6(3). - P. 313-317.

340.Paixão, P. Evaluation of dissolution profile similarity—Comparison between the f2, the

multivariate statistical distance and the f2 bootstrapping methods // P. Paixão, L.F. Gouveia, N.

Silva [et al.] // Eur. J. Pharm. Biopharm. – 2017. – 112. – P. 67–74.

341.Pan, L. A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers / L. Pan, P. Belloni, H.T. Ding [et al.] // Adv Ther. - 2017. - 34(9). - P. 2071-2082.

342.Park, D.B. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects / D.B. Park, K. Jang, J.W. Lee [et al.] // Int J Clin Pharmacol Ther. - 2017. - 55(3). - P. 286-294.

343.Park, J.M. Pharmacokinetics and bioequivalence of two fenofibrate choline formulations in healthy subjects under fed and fasted condition / J.M. Park, S.I. Chae, Y.S. Noh [et al.] // Int J Clin Pharmacol Ther. - 2019. - 57(4). - P. 217-228.

344.Park, J.S. Pharmacokinetic and bioequivalence study of a fixed-dose combination of amlodipine besylate and rosuvastatin calcium compared to co-administration of separate tablets in healthy Korean subjects / J.S. Park, J.Y Jeon., M.G. Kim // Int J Clin Pharmacol Ther. – 2019. - 57(12). – P. 612-622.

345.Park, W.S. Comparative Pharmacokinetic Analysis of Thiamine and Its Phosphorylated Metabolites Administered as Multivitamin Preparations / W.S. Park, J. Lee, T. Hong [et al.] // Clin Ther. - 2016. - 38(10). - P. 2277-2285.

346.PASS: Sample Size & Power [Электронный ресурс]. URL: https://www.ncss.com/software/pass/ (дата обращения 11.05.2020).

347.Pathak, P. Bioequivalence of generic and branded amoxicillin capsules in healthy human volunteers / P. Pathak, VA. Pandit, PP. Dhande [et al.] // Indian J Pharmacol. - 2017. - 49(2). - P. 176-181.

348.Patrick, K.S. Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate / K.S. Patrick, A.B. Straughn // Drug Metab Dispos. - 2016. - 44(3). - P. 418-21.

374

349.Patterson S.D. Bioequivalence and statistics in clinical pharmacology. 2nd ed. / Patterson S.D., Jones B // Boca Raton: CRC Press. - 2016. - 105–106 p.

350.Paumgartten, F.J.R. Nonbioequivalent prescription drug interchangeability, concerns on patient safety and drug market dynamics in Brazil / F.J.R. Paumgartten, A.C. Oliveira // Cien Saude Colet. – 2017. - 22(8). – P. 2549-2558.

351.Pejčić, Z. Adjusted indirect comparisons to assess bioequivalence between generic

clopidogrel products in Serbia / Z. Pejčić, K. Vučićević, A. García-Arieta [et al.] // Br J Clin

Pharmacol. - 2019. - 85(9). - P. 2059-2065.

352.Peters, S.A. Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them / S.A Peters., H. Dolgos // Clin. Pharmacokinet. – 2019. – 58. – P. 1355–1371.

353.Phillips, K. Is There Evidence to Support Brand to Generic Interchange of the Mycophenolic Acid Products? / K. Phillips, P. Reddy, S. Gabardi [et al.] // J Pharm Pract. - 2017.

-30(1). - P. 9-16.

354.Pocock, S.J. Group sequential methods in the design and analysis of clinical trials / S.J. Pocock // Biometrika. - 1977. - 64(2). - P. 191-199.

355.Pop, D.I. Bioequivalence of Two Formulations of Gliclazide in a Randomized Crossover Study in Healthy Caucasian Subjects Under Fasting Conditions / D.I. Pop, M. Oroian, S. Bhardwaj [et al.] // Clin Pharmacol Drug Dev. - 2019. - 8(1). - P. 16-21.

356.Potvin, D. Sequential design approaches for bioequivalence studies with crossover designs / D. Potvin, C.E. Diliberti, W.W. Hauck [et al.] // Pharmaceutical Statistics. – 2008. - 7(4). – P. 245–62.

357.Power TOST-package: power and sample size based on two-one-sided T-test (TOST) procedure for bioequivalence studies by D. Labes [Электронный ресурс] URL: https://www.rdocumentation.org/packages/PowerTOST/versions/1.4-9/topics/power.TOST (дата обращения: 11.05.2020).

358.Prasaja, B. Impact of Truncated Area on Point Estimate and Intra-Subject Variability in Bioequivalence of Dutasteride with Long Half-Life / B. Prasaja, Y. Harahap, W. Lusthom [et al.] // Drug Res (Stuttg). - 2018. - 68(4). - P. 238-240.

359.Prompila, N. Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects / N. Prompila, W. Eiamart, Y. Jumroen [et al.] // Int J Clin Pharmacol Ther.

-2017. - 55(10). - P. 811-817.

360.Pruckner, G.J. Hospitals and the generic versus brand-name prescription decision in the outpatient sector / G.J. Pruckner, T. Schober // Health Econ. – 2018. – 27. – P. 1264–1283.

375

361.Qureshi, I. A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV-0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers / I. Qureshi, M. Lovegren, V. Wirtz [et al.] // Clin Pharmacol Drug Dev. - 2020. - 9(4). - P. 476-485.

362.Radicioni, M. Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers

/M. Radicioni, C. Castiglioni, A. Giori [et al.] // Drug Des Devel Ther. - 2017. - 11(04). - P. 1183-1192.

363.Rainio, R. The content of patient counseling about interchangeable medicines and generic substitution in Finnish community pharmacies - a survey of dispensers / R. Rainio, R. Ahonen, J. Timonen // BMC Health Serv Res. – 2019. - 19(1). – P. 956.

364.Ramírez Correa, G.S. Estudio comparativo, cruzado, al azar, para la determinación de la bioequivalencia entre dos formulaciones de oxcarbazepina en tabletas / G.S. Ramírez Correa, P. Restrepo Valencia, M. Pérez Guzmán [et al.] // Iatreia. - 2009. - 22(3). - P. 205-212.

365.Rasmussen, H.E. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs / H.E. Rasmussen, R. Ma, J.J. Wang [et al.] // Pharm Stat. - 2019. - 18(1). - P. 96-105.

366.Rastogi, V. A Mathematical prediction of pharmacokinetic parameters-an in-vitro approach for investigating pharmaceutical products for IVIVC / V. Rastogi, P. Yadav, N. Lal [et al.] // Future Journal of Pharmaceutical Sciences. - 2018. - 4(2). - P. 175-184.

367.Rediguieri, C.F. Assessing Bioequivalence of Antiepileptic Drugs: Are the Current / C.F. Rediguieri, J.L. Zeredo // J Pharm Pharm Sci. - 2014. - 17(2). - P. 220-228.

368.Refalo, N. Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective / N. Refalo, D. Chetcuti, A. Tanti [et al.] // Saudi Pharm J. - 2017. - 25(2). - P. 280-289.

369.Reigner, B. Generics in transplantation medicine: Randomized comparison of innovator and substitution products containing mycophenolate mofetil // B. Reigner, S. Grange, D. Bentley [et al.] // Int J Clin Pharmacol Ther. – 2019. -57(10). – P. 506-519.

370.Richter, W. Bioequivalence study of two different clopidogrel bisulfate film-coated tablets / W. Richter, A. Erenmemisoglu, M.J. Van der Meer [et al.] // Arzneimittelforschung. - 2009. - 59(6). - P. 297-302.

371.Ring, A. Sample size determination in bioequivalence studies using statistical assurance

/A. Ring, B. Lang, C. Kazaroho [et al.] // British Journal of Clinical Pharmacology. - 2019. - 85(10). - P. 2369-2377.

376

372.Romodanovskii, D.P. Investigation Planning and Bioequivalence evaluation of Angiotensin II Receptor Antagonists / D.P. Romodanovskii, D.V. Goryachev, A.L. Khokhlov [et al.] // Pharm Chem J. - 2019. - 53. - P. 680-684.

373.Romodanovskii, D.P. Planing bioequivalence studies of drugs with narrow therapeutic indices / D.P. Romodanovskii, D.V. Goryachev, Y.V. Olefir [et al.] // Pharm Chem J. - 2017. - 50(12). - P. 814-816.

374.Rottembourg, J. The use of generics in transplantation: Towards rational and safe solutions! / J. Rottembourg, G. Rostoker // Presse Med. – 2018. - 47(3). – P. 199-210.

375.Rouini, M.R. Pharmacokinetics and Bioequivalence Studies of Teriflunomide in Healthy Iranian Volunteers / M.R. Rouini, M. Dibaei, E. Ghasemian [et al.] // Clin Pharmacol Drug Dev.

-2020. - 9(3). - P. 341-345.

376.Saavedra, I. Relative bioavailability study with two oral formulations of topiramate using a validated UPLC-MS/MS method / I. Saavedra, E. Tamayo, A. Gamboa [et al.] // Int J Clin Pharmacol Ther. - 2010. - 48(5). - P. 342-348.

377.Sahajwalla, C.G. Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330mg tablet versus 1-g chewable tablet versus enteral solution in healthy adult male volunteers / C.G. Sahajwalla, E.D. Helton, E.D. Purich [et al.] // J Pharm Sci. - 1995. - 84(5). - P. 627-633.

378.Saito, K.I. Investigation of Bioequivalence Between Brand-name and Generic Irinotecan Products / K.I. Saito, Y. Inoue, Y. Ikegami [et al.] // Anticancer Res. - 2016. - 36(11). - P. 59575963.

379.Saleh, S. Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food / S. Saleh, R. Frey, C. Becker [et al.] // Pulm Circ. - 2016. - 6(03). - P. S66-74.

380.Salunkhe, N.H. Validated RP-HPLC method for quantification of felodipine: Application in a bioequivalence study / N.H. Salunkhe, N.R. Jadhav, S.D. Bhinge [et al.] // Ann Pharm Fr. - 2019. - 77(1). - P. 15-27.

381.Sanjeeva, D.S. Assessing the bioequivalence of analogues of endogenous substances

(«endogenous drugs»): considerations to optimize study design / D.S. Sanjeeva // Br J Clin

Pharmacol. - 2010. - 69. - P. 238–244.

382.Schneider, F. Resolving the physiological conditions in bioavailability and bioequivalence studies: Comparison of fasted and fed state / F. Schneider, M. Grimm, M. Koziolek [et al.] // Eur J Pharm Biopharm. - 2016. - 108(11). - P. 214-219.

383.Schütz, H. Reference datasets for 2-treatment, 2-sequence, 2-period bioequivalence

studies / H. Schütz, D. Labes, A. Fuglsang // AAPS J. – 2014, - 16(6). – P. 1292–1297.

377

384.Schütz, H. Reference Datasets for Studies in a Replicate Design Intended for Average

Bioequivalence with Expanding Limits / H. Schütz, D. Labes, M. Tomashevskiy [et al.] // AAPS

J.- 2020. - 22(2). - P. 44.

385.Schütz, H. ReplicateBE: Average Bioequivalence with Expanding Limits (ABEL) / H. Schütz, M. Tomashevskiy, D. Labes // 2020 [Электронный ресурс]; R package version 1.0.13. URL: https://cran.r-project.org/package=replicateBE (дата обращения 13.05.2020).

386.Schütz, H. Two-stage designs in bioequivalence trials / H. Schütz // European journal of

clinical pharmacology. – 2015. - 71(3). – P. 271–281.

387.Segarra, I. Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees / I. Segarra, P. Modamio,

C.Fernández [et al.] // Front Pharmacol. – 2017. – 8. – P. 488.

388.Seoane-Vazquez, E. Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs / E. SeoaneVazquez, R. Rodriguez-Monguio, R. Hansen [et al.] // Clin Drug Investig. - 2016. -3 6(4). - P. 281-92.

389.Shabbir, S. The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial / S. Shabbir, I.J. Pouliquen, J.H. Bentley [et al.] // Clin Pharmacol Drug Dev. - 2020. - 9(3). - P. 375-385.

390.Shang, D. The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of pitavastatin calcium in healthy Chinese male subjects / D. Shang, S. Deng,

Z.Yao [et al.] // Xenobiotica. -2016. - 46(1). - P. 34-9.

391.Shen, M.Y. Bioequivalence evaluation of sparse sampling pharmacokinetics data using bootstrap resampling method / M.Y. Shen, S.G. Machado // J Biopharm Stat. – 2017. – 27. – P. 257-64.

392.Shutz, H. Sample size estimation for BE studies, bioequivalence Studies in Russia: Pharmacokinetics, Statistics and Analytics, 24 April 2014 [Электронный ресурс] URL: https://bebac.at/lectures/Moscow2014WS2.pdf (дата обращения 11.05.2020).

393.Shutz, H. Sample size estimation, BE Workshop, Moscow, 6 October 2016 [Электронный ресурс] URL: https://bebac.at/lectures/Moscow2016-1.pdf (дата обращения

11.05.2020).

394. Sikes, C. A Single-Dose, Two-Way Crossover, Open-Label Bioequivalence Study of an Amphetamine Extended-Release Oral Suspension in Healthy Adults / C. Sikes, J.G. Stark, R. McMahen [et al.] // J. Atten Disord. - 2020. - 24(3). - P. 414-419.

378

395.Sjögren, E. In Silico Modeling of Gastrointestinal Drug Absorption: Predictive

Performance of Three Physiologically Based Absorption Models / E. Sjögren, H. Thörn, C.

Tannergren // Mol. Pharm. – 2016. – 13. – P. 1763–1778.

396.Skovlund, E. How different can generic drugs be? / E. Skovlund // Tidsskr Nor Laegeforen. – 2019. - 139(16). - doi: 10.4045/tidsskr.19.0383.

397.Soldin, O.P. Sex differences in drug disposition / O.P. Soldin, S.H. Chung, D.R. Mattison

//J Biomed Biotechnol. - 2011. – 1. – P. 1-14.

398.Song, I.D. Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects / I.D. Song, J.S. Kang, H.J. Kim [et al.] // Drug Metab Lett. -2017. - 10(4). - P. 286-294.

399.Sornsuvit, C. Pharmacokinetics and bioequivalence studies of warfarin sodium 5 milligrams tablet in healthy Thai subjects / C. Sornsuvit, N. Niamhun, N. Luengpiansamut [et al.] // International Journal of Pharmacy and Pharmaceutical Sciences. - 2015. - 7(3). - P. 219222.

400.Staatz, C.E. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients / C.E. Staatz, S.E. Tett // Clin Pharmacokinet. – 2015. - 54(10). – P. 9931025.

401.Stojanova, J. Main concepts on bioequivalence and biosimilarity in the Chilean legislation, and current controversies on drug interchangeability / J. Stojanova, M. Lutz, G. Lazcano [et al.] // Medwave. – 2020. - 20(2). – P. 7825.

402.Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs.

[Электронный ресурс] // United States Food and Drug Administration. URL:

https://www.fda.gov/media/71107/download (дата обращения: 11.05.2020).

403.StudySize: software for sample size calculations [Электронный ресурс] URL:http://www.studysize.com/ (дата обращения 11.05.2020).

404.Suarez-Sharp, S. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications / S. Suarez-Sharp, PR. Delvadia, A. Dorantes [et al.] // AAPS J. - 2016. - 18(3). - P. 578-88.

405.Sugihara, M. Analysis of intraand intersubject variability in oral drug absorption in human bioequivalence studies of 113 generic products / M. Sugihara, S. Tageuchi, M. Sugita [et al.] // Mol Pharm. – 2015. – 12. – P. 4405–4412.

406.Tamargo, J. Low quality of some generic cardiovascular medicinal products represents a matter for growing concern / J. Tamargo, G. Rosano // Eur Heart J Cardiovasc Pharmacother. –

2020. - 6(3). – P. 176-187.

379

407.Tamargo, J. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide / J. Tamargo, J.Y. Le Heuzey, P. Mabo // Eur J Clin Pharmacol. – 2015. - 71(5). – P. 549-67.

408.Tang, F. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects / F. Tang, R. Zhou, Z. Cheng [et al.] // Acta Pharm Sin B. - 2016. - 6(1). - P. 71-8.

409.Tanguay, M. Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule / M. Tanguay, J. Girard, C. Scarsi [et al.] // Clin Pharmacol Drug Dev. - 2019. - 8(4). - P. 521-528.

410.Thomas, D. Investigation of bioequivalence, safety, and tolerability of a fixed-dose combination of nifedipine GITS and candesartan compared with the corresponding loose-dose combination under fed conditions / D. Thomas, Y. Liu, H. Stein [et al.] // Int J Clin Pharmacol Ther. - 2019. - 57(8). - P. 420-428.

411.Thudium, K. Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers / K. Thudium, J. Gallo, E. Bouillaud [et al.] // Clin Pharmacol. - 2015. - 7. - P. 11-17.

412.Tian, S. A Bioequivalence Test by the Direct Comparison of Concentration-versus-Time Curves Using Local Polynomial Smoothers / S. Tian, HH. Chang, D. Orange [et al.] // Comput Math Methods Med. - 2016. - 2016. - doi.org/10.1155/2016/4680642.

413.Tian, Y. Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study / Y. Tian, B. Reichardt, D. Dunkler [et al.] // Sci Rep. - 2020. - 10(1). – P. 5964.

414.Ting, T.Y. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard / T.Y. Ting, W. Jiang, R. Lionberger [et al.] // Epilepsia. – 2015. - 56(9). – P. 1415-24.

415.Title 21—Food and Drugs Chapter I—Food and Drug Administration Department of Health and Human Services Subchapter D—Drugs for Human Use, Part 320 — Bioavailability and Bioequivalence Requirements, Subpart A—General Provisions, Sec. 320.1 Definition’s

preparations in healthy subjects / R.R. Tjandrawinata, E. Setiawati, R.S. Putri [et al.] // Drug Des Devel Ther. - 2014. - 8. - P. 1249–1255.

380